Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers…
PALO ALTO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary…
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE…
CEO James Walesa to Provide Organizational and Industry Update at Conference San Antonio, Texas, Sept. 13, 2023 (GLOBE NEWSWIRE) --…
OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the…
-- Presentation to educate on Portable Neuromodulation Stimulator (PoNS®) Therapy, highlighting the differentiation from other neuromodulation technologies, and the science…
Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense) BERKELEY, Calif. and MAINZ, Germany,…
MONTREAL, Sept. 13, 2023 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the closing of the company’s Series D financing round…
DENVER, Sept. 12, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (the “Company” or “InnovAge”) (Nasdaq: INNV), an industry leader in…
JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology…